MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591280 | Name: Bendazac lysine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bendazac lysine reduces the affect of the cataract.

Chemical Structure

Bendazac lysine
Bendazac lysine
CAS#81919-14-4 (lysine)

Theoretical Analysis

MedKoo Cat#: 591280

Name: Bendazac lysine

CAS#: 81919-14-4 (lysine)

Chemical Formula: C22H28N4O5

Exact Mass: 0.0000

Molecular Weight: 428.49

Elemental Analysis: C, 61.67; H, 6.59; N, 13.08; O, 18.67

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 550.00 2 weeks
10g USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
20187-55-7 (free acid) 81919-14-4 (lysine)
Synonym
Bendazac lysine; AF 1934; AF-1934; AF1934
IUPAC/Chemical Name
L-Lysine, 2-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)acetate (1:1)
InChi Key
OCOCFNMFLNFNIA-ZSCHJXSPSA-N
InChi Code
InChI=1S/C16H14N2O3.C6H14N2O2/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12;7-4-2-1-3-5(8)6(9)10/h1-9H,10-11H2,(H,19,20);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1
SMILES Code
N[C@@H](CCCCN)C(O)=O.O=C(O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 428.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Balfour JA, Clissold SP. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs. 1990 Apr;39(4):575-96. doi: 10.2165/00003495-199039040-00007. PMID: 2190795. 2: Rovei V, Campistron G, Dueymes JM, Ego D, Conte JJ, Houin G. Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency. Eur J Clin Pharmacol. 1987;33(3):303-10. doi: 10.1007/BF00637567. PMID: 3691618. 3: Soldo L, Ruggieri A, Milanese C, Pinza M, Guglielmotti A. Bendazac lysine inhibition of human lens epithelial cell adhesion to polymethylmethacrylate intraocular lenses. Ophthalmic Res. 2004 May-Jun;36(3):145-50. doi: 10.1159/000077327. PMID: 15103205. 4: Iwakiri K, Hata M, Miura Y, Numano K, Yuge M, Sasaki E. Allergic contact dermatitis due to bendazac and alclometasone dipropionate. Contact Dermatitis. 1999 Oct;41(4):218-39. doi: 10.1111/j.1600-0536.1999.tb06133.x. PMID: 10515101. 5: Hockwin O, Laser H, De Gregorio M, Carrieri MP. Bendazac lysine in selected types of human senile cataract. A long-term double-masked placebo-controlled clinical trial with multilinear densitometric image analysis of Scheimpflug photographs. Ophthalmic Res. 1989;21(3):141-54. doi: 10.1159/000266799. PMID: 2674821. 6: Rovei V, Escourrou J, Campistron G, Ego D, Thiola A, Ribet A, Houin G. The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis. Eur J Clin Pharmacol. 1988;35(4):391-6. doi: 10.1007/BF00561370. PMID: 3197747. 7: Scorza Barcellona P, Campana A, Caranti S, D'Onofrio E, Silvestrini B. Pretreatment with bendazac attenuates retinal damage induced by intense light in rats. Pharmacol Res. 1991 Jul;24(1):105-12. doi: 10.1016/1043-6618(91)90070-e. PMID: 1946139. 8: Pandolfo L, Livrea MA, Bono A. Effects of bendazac L-lysine salt on X-ray- induced cataract in the rabbit lens. Exp Eye Res. 1986 Feb;42(2):167-75. doi: 10.1016/0014-4835(86)90040-0. PMID: 3699106. 9: Benitez del Castillo JM, Jimenez-Alfaro I, Ortega P, Castillo A, Diaz D, Toledano N, Garcia-Sanchez J. Effect of bendazac lysine on lens and retina in diabetics. Doc Ophthalmol. 1994;86(4):387-93. doi: 10.1007/BF01204597. PMID: 7835176. 10: Rodríguez Rodríguez E, Prieto de Paula JM, Cancelo Suárez P, Echevarría Iturbe C. Hepatitis crónica activa por bendazaco [Chronic active hepatitis due to bendazac]. Rev Clin Esp. 1994 Aug;194(8):657-8. Spanish. PMID: 7938854. 11: Testa M, Iuliano G, Marino E, Buongiovanni C, Paolercio F, Trapanese A, Mortow P. Bendazac and benzydamine for treatment of cataract: individualized therapy by the "BLOA test". J Ocul Pharmacol. 1986 Summer;2(3):251-66. doi: 10.1089/jop.1986.2.251. PMID: 3503111. 12: Guglielmotti A, Capezzone De Joannon A, Cazzolla N, Marchetti M, Soldo L, Cavallo G, Pinza M. Radical scavenger activity of bendazac, an anticataract non- steroidal anti-inflammatory agent. Pharmacol Res. 1995 Dec;32(6):369-73. doi: 10.1016/s1043-6618(05)80042-8. PMID: 8736488. 13: Yu JX, Yin XX, Shen JP, Qiu J, Yin HL, Jiang SJ. Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1231-8. doi: 10.1111/j.1440-1681.2006.04515.x. PMID: 17184506. 14: Lewis BS, Harding JJ. The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis. Exp Eye Res. 1988 Aug;47(2):217-25. doi: 10.1016/0014-4835(88)90005-x. PMID: 3409993. 15: Alcalde M, Garcia-Diaz M, Najarro F, Donoso MS, Cebria L, Pascasio JM. Hepatotoxicity due to lysine salt of bendazac. Scand J Gastroenterol. 1996 Feb;31(2):206-8. doi: 10.3109/00365529609031987. PMID: 8658045. 16: Valeri P, Palmery M, Martinelli B, Catanese B. Absorption of bendazac lysine after topical application to the rabbit eye. Pharmacol Res Commun. 1987 Aug;19(8):517-25. doi: 10.1016/0031-6989(87)90089-0. PMID: 3432319. 17: Shen H, Gou S, Shen J, Zhu Y, Zhang Y, Chen X. Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2115-8. doi: 10.1016/j.bmcl.2010.02.061. Epub 2010 Feb 19. PMID: 20223660. 18: Silva MP, Mira L, Lima J, Manso CF. Kinetics of the inhibition of xanthine dehydrogenase and of the reversible and irreversible forms of xanthine oxidase by silibinin and bendazac. Environ Toxicol Pharmacol. 1996 Jul 15;1(4):279-84. doi: 10.1016/1382-6689(96)00021-X. PMID: 21781693. 19: Ciancarelli-Tozzi MG, Silvestrini B, Finazzi-Agro A. Photosensitized haemolysis of human erythrocytes is reduced by bendazac. Drugs Exp Clin Res. 1989;15(5):219-22. PMID: 2791873. 20: Marques C, Ramalho JS, Pereira P, Mota MC. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol. 1995;90(4):395-404. doi: 10.1007/BF01268125. PMID: 8620822.

View History

Bendacort

Bendacort